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Background: Gastrointestinal stromal tumors (GISTs) represent 85% of all mesenchymal neoplasms that affect the
gastrointestinal (GI) tract. These GISTs range in size from small lesions to large masses. Often they are clinically silent
until they reach a significant size, so their discovery is usually incidental.
Case presentation: A 67-year-old man was admitted at our general surgery department with a persistent
abdominal pain in the left hypochondrium, associated with nausea and vomiting. Clinical examination revealed a
palpable mass in the epigastrium and in the left hypochondrium, which was approximately 40 cm long.
Ultrasonography and computed tomography of the abdomen showed a large mass of 40 × 25 cm, which extended
from the posterior wall of the stomach to the spleen, involving the body and the tail of the pancreas. The patient
underwent en-block resection of the mass, sleeve resection of the stomach, and distal pancreatectomy-
splenectomy. The histopathology of the resected specimen was consistent with a gastrointestinal stromal tumor of
the stomach (positive for CD 117) with a high risk of malignancy (mitotic count >5/50 high-power fieldand Ki67/
Mib1 >10%). The postoperative course was uneventful and treatment with imatinib mesylate began immediately.
The patient appears to be disease free after four years.
Conclusions: Giant GISTs of the stomach are rare. Surgical resection with curative intent is feasible. The
combination of surgical resection and imatinib can provide long-termdisease-free survival. An R0 resection is the
best achievable treatment, therefore the patient should be evaluated over time for potential resectability.
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Gastrointestinal stromal tumors (GISTs) represent 85% of
all mesenchymal neoplasms that affect the gastrointestinal
(GI) tract [1].
In the past, these tumors were classified as leiomyomas,
leiomyosarcomas, or leiomyoblastomas. Only recently,
with the help of immunohistochemistry, have GISTs be-
come considered a separate entity. These tumors are be-
lieved to arise from the KIT (CD117) positive interstitial
cell of Cajal, the pacemaker cell of the GI tract [2,3].* Correspondence: schaky@hotmail.it
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distribution, and reproduction in any mediumApproximately 85% of GISTs harbor an activating KIT
mutation, which leads to constitutive activation of KIT
and its tyrosine kinase function. Approximately 3% to 5%
of GISTs instead carry a mutation in the PDGFRa gene,
and about 10% to 15% of the tumors contain wild-type
forms of the KIT and PDGFRa proto-oncogenes [4-6].
These tumors are located primarily in the stomach
(60% to 70%) and their discovery is often incidental [7].
GISTs range in size from small lesions to large masses.
They are clinically silent until they reach a significant
size; this is why their discovery is usually incidental [1].
In many cases, GISTs present with abdominal pain, GI
bleeding or palpable mass. In other cases, they may be
revealed because of a complication: bowel obstruction,
spontaneous rupture into the peritoneal cavity leading totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 2 Coronal computed tomogram, showing a large mass
of 40 × 25 cm, which extended from the posterior wall of the
stomach to the spleen, enveloping the body and the tail of
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We report an unusual case of a giant GIST that caused a
proximal bowel obstruction.
Case presentation
A 67-year-old man was admitted to the Department of
General Surgery of the University of Catania with a per-
sistent abdominal pain in the left hypochondrium associ-
ated with nausea, vomiting, and weight loss (5 kg in two
months). Clinical examination revealed a palpable mass in
the epigastrium and in the left hypochondrium, which was
approximately 40 cm long. The abdominal mass appeared
to be fixed to adjacent structures, with its limits poorly
defined.
All routine blood test results and levels of tumor
markers (CEA, CA 19–9, α-fetoprotein) were within the
normal ranges. Ultrasonography and computed tomog-
raphy of the abdomen showed a large mass of 40 × 25 cm,
which extended from the posterior wall of the stomach to
the spleen, enveloping the body and the tail of the pan-
creas (Figures 1 and 2). Moreover, the mass was in close
proximity to the left colic flexure.
After appropriate fluid resuscitation and positioning
of a naso-gastric tube, the patient was urgently taken to
the operating room for exploration. A bilateral subcostal
approach was chosen. The giant mass occupied the centralFigure 1 Sagittal computed tomogram, showing the extent of
tumor and the compression of the left colonic flexure.
the pancreas.abdomen and displaced the stomach anteriorly. The
tumor abutted surrounding structures closely, especially
the left colic flexure, which was compressed. There was
no evidence of liver or peritoneal metastasis. After division
of the gastro-colic ligament, it became clear that the giant
mass derived from the posterior wall of the stomach and
encased the body and the tail of the pancreas without
infiltrating the celiac trunk or the mesenteric vessels. An
intraoperative biopsy of the mass revealed an uncertain
‘spindle cell tumor’.
Once the technical feasibility of the intervention had
been established, the splenic vessels were ligated at the
superior margin of the pancreas, and the patient was
subjected to en-block resection of the mass by distal
spleno-pancreatectomy and sleeve resection along the
large curve of the stomach. The mass was solid, mea-
sured 37 × 24 × 13 cm, weighed 8.5 kg, and had cyst and
hemorrhagic areas; it did not infiltrate the spleen or pan-
creas (Figure 3).
Final histopathology of the resected specimen showed a
spindle cell cancer with a mitotic count of 5/50 high-
power field and a high proliferation index Ki67/Mib1
>10%. Immunohistochemistry revealed that the tumor
was positive for CD 117/c-kit and for CD 34, and negative
for desmin, vimentin, smooth muscle actin, muscle-
Figure 3 The removed tumor.
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Hence, the final diagnosis was giant GIST of the stomach
with high risk of malignancy.
The postoperative course was uneventful and treat-
ment with imatinib mesylate 400 mg once daily started
immediately. The patient appears to be disease free after
four years.
Discussion
Gastrointestinal stromal tumors (GISTs) are rare mesen-
chymal neoplasms with uncertain biological behavior that
arise in the wall of the gastrointestinal tract. Despite
recent progress made in the diagnosis of these tumors,
their nosological classification remains challenging, owing
to their high phenotypic polymorphism, and their ability
to acquire a wide range of clinical phenotypes, from
indolent-benign to malignant with high metastatic cap-
acity. This peculiarity reflects the inability to predict the
outcome of patients with these tumors and strongly limits
prognostic evaluation.
GISTs may present in a number of different ways and
are often diagnosed incidentally. Symptoms caused by
GISTs are related to their location, leading to both mass
effects and intraluminal bleeding. Large GISTs may
cause vague abdominal discomfort, pain, bloating, early
satiety, and, in rare cases, occlusion, compression of
surrounding structures, and peritonitis due to spontan-
eous rupture into the peritoneum [8,9]. In some cases,
the core of a large tumor leads to an intralesionaldegeneration, necrosis, or abscess development [10]. We
report the case of a very large GIST of the stomach with
an uncommon presentation, bowel obstruction due to
left colic flexure compression.
GISTs, together with other soft tissue tumors, should be
considered in the differential diagnosis of patients with an
uncertain abdominal mass, even if a pathological diagnosis
of GIST is not certain before or during surgery. For an un-
certain abdominal mass, preoperative biopsy is commonly
performed, but for GISTs the consideration for biopsy
should be based on the extent of the disease. For localized
or potentially resectable GISTs, for which preoperative
imatinib is not being considered, preoperative pathological
confirmation should not be necessary [1]. A biopsy is ad-
visable for definitively unresectable or metastatic disease
and in cases where preoperative therapy with imatinib is
indicated because of marginally resectable disease or po-
tentially resectable disease in high-risk patients [1]. Endo-
scopic ultrasound-guided fine-needle aspiration biopsy is
preferred over percutaneous biopsy, owing to limited
hemorrhage, the risk of tumor rupture, and dissemination.
However, many pathologists might not produce a diagno-
sis using a fine-needle aspirate and a core-needle biopsy
might be inconclusive if a necrotic or hemorrhagic portion
of the tumor is sampled [1].
In our case, in spite of the large size, we performed
only an intraoperative biopsy of the mass, as we needed
to proceed with surgical excision, owing to the concomi-
tant bowel obstruction. The intraoperative pathology
was uncertain as it only showed ‘spindle cell cancer’.
After removal of any suspected GIST, postoperative
pathology assessment is essential to confirm the diagnosis
and to determine the correct size and the mitotic index,
which are very important for the stratification of risk [11].
Surgery remains the therapy of choice for patients with
primary GIST with no evidence of metastasis, and should
be the initial therapy if the tumor is technically resectable
and associated with an acceptable morbidity risk [1].
The goal of the operation is complete gross resection with
a negative microscopic margin (R0 resection) without
bleeding and rupture of the pseudocapsule [12].
The detection of microscopically positive margins in
the case of large GISTs (>10 cm) is of dubious value,
since during surgical maneuvers there is a possible ex-
foliation of neoplastic cells directly into the peritoneum
[13]. Furthermore, there is no clear association between
microscopically positive margins and poorer survival out-
comes. Excision should be considered on a case-by-case
basis, and often depends on the extremity of the first
operation, as judged by the multidisciplinary team.
The decision to use preoperative imatinib is justified
for locally advanced GISTs and for unresectable recur-
rent or metastatic disease [1]. Preoperative imatinib is
also an option to facilitate function-preserving surgery
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[14,15]. The role of preoperative imatinib for treating
primary localized GIST is questionable, as there is no clear
evidence on the role of preoperative imatinib to obtain R0
resection. It is believed that exposure to preoperative
imatinib may lead to a downregulation of c-kit expression
with consequently selection of imatinib resistant clones of
cancer cells, which may preclude the benefit of the surgi-
cal resection and the adjuvant therapy [16]. The role of
new drugs (sunitinib) is still under evaluation in patients
with progressive disease [17]. However, the optimal dur-
ation of preoperative therapy and the optimal timing of
resection remain unknown. Another dangerous side effect
can be the intralesional hemorrhage inside a giant mass,
with hemoperitoneum or perforation [18].
Conclusions
The surgical management of a giant GIST is a complex
issue. We recommend that patients be continually eva-
luated by the surgical team for a possible resectability
because we believe that the best strategy is ‘surgery
when possible’, aimed at obtaining an R0 resection when
possible. Even in this case of giant GIST of the stomach,
an R0 resection can be safely achieved.
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